Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome
NCT05704400
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Nephrotic Syndrome
Interventions
DRUG:
Rituximab Biosimilar ABP 798
DRUG:
Daratumumab
Sponsor
Istituto Giannina Gaslini